Code Biotherapeutics is pioneering a novel class of precision genetic medicines through its proprietary 3DNA® delivery platform. This targeted, non-viral system is designed to address significant challenges in the delivery of genetic therapies, such as dose-related toxicity, off-target effects, and immunogenicity. The 3DNA platform utilizes a multivalent structure that allows for the attachment of targeting molecules and nucleic acid-based therapeutics, enhancing both the specificity and potency of the treatment. By leveraging receptor-mediated processes for cell internalization, 3DNA ensures that genetic payloads are efficiently delivered to the cytoplasm and subsequently localized to the cell nucleus, where they can exert their therapeutic effects.

The 3DNA platform also offers advantages in terms of re-dosability and manufacturing. Unlike traditional viral vector approaches, which can trigger immune responses and limit repeat dosing, 3DNA is engineered to avoid such issues, allowing for potential re-administration of therapies. Its manufacturing process is straightforward and scalable, enabling the production of 3DNA in bulk and facilitating the formulation of various genetic medicines. This innovative platform has shown promise in delivering complex gene constructs, with the capability to target a range of diseases, including Duchenne Muscular Dystrophy (DMD) and other conditions affecting the lungs, pancreas, and liver. Overall, Code Biotherapeutics aims to transform the landscape of genetic medicine with its advanced delivery technologies.

United States

Code Bio is developing a transformational, new class of precision genetic medicines to treat life-threatening diseases.

Code Biotherapeutics

Company Details